

Resource Summary Report

Generated by NIF on Aug 1, 2026

PE anti-human CD64

RRID:AB_314491

Type: Antibody

Proper Citation

BioLegend Cat# 305007, RRID:AB_314491

Antibody Information

URL: http://antibodyregistry.org/AB_314491

Proper Citation: BioLegend Cat# 305007, RRID:AB_314491

Target Antigen: CD64

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD64

Description: This monoclonal targets CD64

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone 10.1

Antibody ID: AB_314491

Vendor: BioLegend

Catalog Number: 305007

Alternative Catalog Numbers: 305008

Record Creation Time: 20250819T234907+0000

Record Last Update: 20250820T063129+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD64.

No alerts have been found for PE anti-human CD64.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. Cell reports. Medicine, 6(6), 102141.

Stewart ML, et al. (2025) CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia. Cell reports. Medicine, 102526.

Bennard A, et al. (2023) IL-3 orchestrates ulcerative colitis pathogenesis by controlling the development and the recruitment of splenic reservoir neutrophils. Cell reports, 42(6), 112637.

Chen S, et al. (2022) Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1. Cell metabolism, 34(11), 1843.